Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LENZ Therapeutics, Inc. (LENZ : NSDQ)

• Company Description    Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Lenz Therapeutics Inc., formerly known as Graphite Bio Inc., is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 42

• Price / Volume Information    Yesterday's Closing Price: $41.33 Daily Weekly Monthly 20 Day Moving Average: 478,020 shares Shares Outstanding: 28.52 (millions) Market Capitalization: $1,178.96 (millions) Beta: 0.45 52 Week High: $42.77 52 Week Low: $16.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.04% -0.74% 12 Week 37.65% 25.03% Year To Date 43.18% 26.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 Lomas Santa Fe Dr. Suite 300 - Solana Beach,CA 92075 USA ph: 858-925-7000 fax: - ir@lenz-tx.com https://lenz-tx.com

• General Corporate Information    Officers Evert Schimmelpennink - Chief Executive Officer;President;Secretary and Di Jeff George - Chairperson Daniel Chevallard - Chief Financial Officer Jeff George - Director Frederic Guerard - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52635N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 28.52 Most Recent Split Date: 3.00 (0.14:1) Beta: 0.45 Market Capitalization: $1,178.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.63 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 31.08% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.71 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.50% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -25.63 03/31/25 - -23.74 12/31/24 - -24.56 ROA 06/30/25 - -24.43 03/31/25 - -22.65 12/31/24 - -23.17 Current Ratio 06/30/25 - 20.54 03/31/25 - 23.09 12/31/24 - 20.36 Quick Ratio 06/30/25 - 20.54 03/31/25 - 23.09 12/31/24 - 20.36 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -1,037.94 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 7.24 03/31/25 - 6.97 12/31/24 - 7.42 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©